News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Global Market News, Articles and Videos with Contenting
Global market news refers to the news, articles, and videos that focus on global markets. This news covers a wide range of topics, including global economic trends, political developments, and company and industry performance. It also covers news related to currencies, stocks and commodities, as well as emerging markets and other investments. These news items can be found in various sources, such as newspapers, magazines, websites, and television networks. By reading these news sources, investors can gain valuable insights into the global markets and make informed decisions when investing.
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 - ForexTV
Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company’s product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which currently faces the minimum tariff of 10% on goods imported to the U.S. A 10% tariff on pharmaceuticals would raise the cost of biosimilars from Alvotech imported to the U.S. for customers by less than 1% of Alvotech’s expected total product revenues in 2025. Furthermore, according to contracted terms, customers are responsible for all costs of transport and import duties to the U.S., and these costs are therefore not expected to be paid by Alvotech. “With the lingering uncertainty in the market about tariffs, and companies planning accordingly, I feel that it is important to communicate clearly about this issue. We manufacture all our biosimilars in Iceland, a country which imports more goods from the U.S. than it exports to the U.S., and is therefore only subject to the minimum 10% tariff introduced in April. Because a favorable U.S. trade balance is one of the key objectives of the new tariff policy, we have currently no reason to believe that a much higher tariff would be applied to pharmaceuticals from Iceland than on other goods. I expect that policy makers will also take into account that biosimilars offer the most cost-effective means of increasing patient access and lowering the cost of vital biologics for U.S. patients,” said Robert Wessman, chairman and CEO of Alvotech. “The estimated impact of a 10% tariff on our sales to the U.S. in the second half of the year would be less than 1% of our expected product revenues in 2025, and these cost would not be paid by Alvotech. Looking beyond 2025, given anticipated product launches and increased sales, we estimate that the impact would still constitute a low single digit percentage of Alvotech’s anticipated total product revenues.” About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube. Alvotech Forward Looking StatementsCertain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “aim” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) material impacts of import duties or restrictions on import in markets where Alvotech’s products are sold or expected to be sold; (2) Alvotech’s ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech’s estimates of expenses and profitability; (6) Alvotech’s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech’s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech’s ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech’s current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech’s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech’s ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company’s business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONSBenedikt Stefansson, VPalvotech.ir@alvotech.com
ACM Research Reports First Quarter 2025 Results - ForexTV
FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced packaging applications, today reported financial results for its first quarter ended March 31, 2025. “Our first quarter results mark a good start to 2025. We delivered 13% year-over-year revenue growth, solid profitability, and positive cash flow from operations,” said Dr. David Wang, President and Chief Executive Officer of ACM. “We achieved several strategic milestones: including the qualification of our high-temperature SPM tool by a leading logic customer in China, customer acceptance for our backside/bevel etch tool from a U.S. customer, and we received the 2025 3D InCites Technology Enablement Award for our proprietary Ultra ECP ap-p tool, which we believe is the world’s first to utilize horizontal plating for panel applications. These achievements highlight ACM’s technology leadership in both front-end processing and advanced packaging applications, which we believe will allow us to play a key role as the global industry demands innovation to advance the ever-evolving semiconductor requirements for AI.” “For 2025, we expect incremental revenue contribution from Tahoe, SPM, and furnace tools; and progress in customer evaluations of Track, PECVD, and panel-level packaging platforms. We believe ACM’s focused effort on developing world-class tools across our customer base will also support our efforts for additional major customer wins in global markets. We are also investing in our Oregon facility to serve as a base for customer evaluations, technology development and initial production for our global customers.” Three Months Ended March 31, GAAP Non-GAAP(1) 2025 2024 2025 2024 (dollars in thousands, except EPS)Revenue$172,347 $152,191 $172,347 $152,191 Gross margin 47.9% 52.0% 48.2% 52.5% Income from operations$25,777 $25,232 $35,594 $39,801 Net income attributable to ACM Research, Inc.$20,380 $17,433 $31,279 $34,597 Basic EPS$0.32 $0.28 $0.49 $0.56 Diluted EPS$0.30 $0.26 $0.46 $0.52 (1) Reconciliations to U.S. generally accepted accounting principles (“GAAP”) financial measures from non-GAAP financial measures are presented below under “Reconciliation of GAAP to Non-GAAP Financial Measures.” Non-GAAP financial measures exclude stock-based compensation and, with respect to net income (loss) attributable to ACM Research, Inc. and basic and diluted earnings per share, also exclude unrealized gain (loss) on short-term investments. Outlook ACM is maintaining its revenue guidance range of $850 million to $950 million for fiscal year 2025. This expectation is based on ACM management’s current assessment of the continuing impact from international trade policy, together with various expected spending scenarios of key customers, supply chain constraints, and the timing of acceptances for first tools under evaluation in the field, among other factors. Operating Highlights and Recent Announcements Shipments. Total shipments in the first quarter of 2025 were $157 million, compared to $245 million for the first quarter of 2024. This decrease is due in part to customer pull-ins in the fourth quarter of 2024, which contributed to stronger total shipments for that period. For reference, combined total shipments for the fourth quarter of 2024 and the first quarter of 2025 grew by 8.9% versus the prior year periods. We anticipate a return to year-on-year growth in total shipments for the second quarter of 2025. Total shipments include deliveries for revenue in the quarter and deliveries of first tool systems awaiting customer acceptance for potential revenue in future quarters.Qualification of High-Temp SPM Tool in China. ACM’s single-wafer high-temperature SPM tool was qualified by a key logic device manufacturer in mainland China. Featuring a proprietary nozzle that reduces acid mist and maintenance needs, the tool enhances particle control and system uptime. It supports wet etching and wafer cleaning for technology nodes at 28nm and below. ACM has now delivered SPM tools to 13 customers.Recognized for Innovation in High-Volume Fan-Out Panel-Level Packaging Solutions. ACM won the 2025 3D InCites Technology Enablement Award for its Ultra ECP ap-p tool, the first commercially available high-volume copper deposition system for the large panel market. This innovative system supports advanced panel sizes and delivers high uniformity through ACM’s proprietary horizontal plating approach, which we expect to help address integration challenges in advanced semiconductor packaging.Appointment of New Board Member. ACM appointed Charlie Pappis to its Board of Directors, effective March 15, 2025. First Quarter 2025 Financial Summary Unless otherwise noted, the following figures refer to the first quarter of 2025 and comparisons are with the first quarter of 2024. Revenue was $172.3 million, up 13.2%, reflecting higher sales of single wafer cleaning, Tahoe and semi-critical cleaning equipment and ECP (front-end and packaging), furnace and other technologies.Gross margin was 47.9% versus 52.0%. Non-GAAP gross margin, which excludes stock-based compensation, was 48.2% versus 52.5%. Gross margin exceeded ACM’s previously disclosed long-term business model target range of 42% to 48%. ACM expects gross margin to vary from period to period due to a variety of factors, such as product mix, currency impacts and sales volume.Operating expenses were $56.8 million, up 5.4%. Operating expenses as a percentage of revenue decreased to 32.9% from 35.4%. Non-GAAP operating expenses, which exclude the effect of stock-based compensation, were $47.5 million, up 18.4%. Non-GAAP operating expenses as a percentage of revenue increased to 27.6% from 26.3%.Operating income was $25.8 million, up 2.2%. Operating margin was 15.0% compared to 16.6%. Non-GAAP operating income, which excludes the effect of stock-based compensation, was $35.6 million, a decrease of 10.6%. Non-GAAP operating margin, which excludes stock-based compensation, was 20.7% compared to 26.2%.Unrealized loss on short-term investments was $1.1 million, compared to $2.6 million. Unrealized loss reflects the change in market value of the investments by ACM’s principal operating subsidiary, ACM Research (Shanghai), Inc. The value is marked-to-market quarterly and is excluded in the non-GAAP financial metrics.Income tax expense was $2.2 million, compared to $4.4 million.Net income attributable to ACM Research, Inc. was $20.4 million, compared to $17.4 million. Non-GAAP net income attributable to ACM Research, Inc., which excludes the effect of stock-based compensation and unrealized loss on short-term investments, was $31.3 million, compared to $34.6 million.Net income per diluted share attributable to ACM Research, Inc. was $0.30, compared to $0.26. Non-GAAP net income per diluted share, which excludes the effect of stock-based compensation and unrealized loss on short-term investments, was $0.46, compared to $0.52.Cash and cash equivalents, plus restricted cash and short-term and long-term time deposits were $498.4 million at March 31, 2025, compared to $441.9 million at December 31, 2024. Conference Call Details A conference call to discuss results will be held on Thursday, May 8, 2025, at 8:00 a.m. Eastern Time (8:00 p.m. China Time). To join the conference call via telephone, participants must use the following link to complete an online registration process. Upon registering, each participant will receive email instructions to access the conference call, including dial-in information and a PIN number allowing access to the conference call. This pre-registration process is designed by the operator to reduce delays due to operator congestion when accessing the live call. Online Registration: https://register-conf.media-server.com/register/BI300a7bc629bd43d98fcb1268d481b156 Participants who have not pre-registered may join the webcast by accessing the link at ir.acmr.com/news-events/events. A live and archived webcast will be available on the Investors section of the ACM website at www.acmr.com. Use of Non-GAAP Financial Measures ACM presents non-GAAP gross margin, operating expenses, operating income, net income attributable to ACM Research, Inc. and basic and diluted earnings per share as supplemental measures to GAAP financial measures regarding ACM’s operational performance. These supplemental measures exclude the impact of stock-based compensation, which ACM does not believe is indicative of its core operating results. In addition, non-GAAP net income attributable to ACM Research, Inc. and basic and diluted earnings per share exclude the effect of stock-based compensation and unrealized gain (loss) on short-term investments, which ACM also believes are not indicative of its core operating results. A reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure is provided below under “Reconciliation of GAAP to non-GAAP Financial Measures.” ACM believes these non-GAAP financial measures are useful to investors in assessing its operating performance. ACM uses these financial measures internally to evaluate its operating performance and for planning and forecasting of future periods. Financial analysts may focus on and publish both historical results and future projections based on the non-GAAP financial measures. ACM also believes it is in the best interests of investors for ACM to provide this non-GAAP information. While ACM believes these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with ACM’s consolidated financial statements prepared in accordance with GAAP. Forward-Looking Statements Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on ACM management’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings ACM makes with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by ACM. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. ACM undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events. About ACM Research, Inc. ACM develops, manufactures and sells semiconductor process equipment spanning cleaning, electroplating, stress-free polishing, vertical furnace processes, track, PECVD, and wafer- and panel-level packaging tools, enabling advanced and semi-critical semiconductor device manufacturing. ACM is committed to delivering customized, high-performance, cost-effective process solutions that semiconductor manufacturers can use in numerous manufacturing steps to improve productivity and product yield. For more information, visit www.acmr.com. © ACM Research, Inc. ULTRA ECP ap and the ACM Research logo are trademarks of ACM Research, Inc. For convenience, these trademarks appear in this press release without ™ symbols, but that practice does not mean that ACM will not assert, to the fullest extent under applicable law, its rights to the trademarks. For investor and media inquiries, please contact: In the United States:The Blueshirt Group Steven C. Pelayo, CFA (360)808-5154 steven@blueshirtgroup.co In China:The Blueshirt Group Asia Gary Dvorchak, CFA +86 (138) 1079-1480 gary@blueshirtgroup.co ACM RESEARCH, INC.Condensed Consolidated Balance Sheets March 31, 2025 December 31, 2024 (Unaudited) (In thousands)Assets Current assets: Cash and cash equivalents$457,240 $407,445 Restricted cash 10,586 3,865 Short-term time deposits 17,202 17,277 Short-term investment 18,319 19,373 Accounts receivable, net 387,849 387,045 Other receivables 35,050 41,859 Inventories, net 609,567 597,984 Advances to related party 1,384 1,024 Prepaid expenses and other current assets 10,677 7,507 Total current assets 1,547,874 1,483,379 Property, plant and equipment, net 277,065 269,272 Operating lease right-of-use assets, net 17,747 14,038 Intangible assets, net 2,997 3,461 Long-term time deposits 13,393 13,275 Deferred tax assets 16,457 14,781 Long-term investments 54,814 37,063 Other long-term assets 3,421 20,452 Total assets$1,933,768 $1,855,721 Liabilities and Equity Current liabilities: Short-term borrowings$24,951 $32,814 Current portion of long-term borrowings 67,935 44,472 Related party accounts payable 19,285 16,133 Accounts payable 116,441 139,294 Advances from customers 241,456 243,949 Deferred revenue 10,781 8,537 Income taxes payable 6,168 12,779 FIN-48 payable 19,483 19,466 Other payables and accrued expenses 118,814 121,657 Current portion of operating lease liability 3,564 2,132 Total current liabilities 628,878 641,233 Long-term borrowings 134,540 105,525 Long-term operating lease liability 6,149 3,840 Other long-term liabilities 8,848 9,217 Total liabilities 778,415 759,815 Commitments and contingencies Equity: Stockholders’ equity: Class A Common stock 6 6 Class B Common stock 1 1 Additional paid-in capital 700,191 677,476 Retained earnings 280,380 260,000 Statutory surplus reserve 30,514 30,514 Accumulated other comprehensive loss (61,946) (63,372)Total ACM Research, Inc. stockholders’ equity 949,146 904,625 Non-controlling interests 206,207 191,281 Total equity 1,155,353 1,095,906 Total liabilities and equity$1,933,768 $1,855,721 ACM RESEARCH, INC.Condensed Consolidated Statements of Operations and Comprehensive Income Three Months Ended March 31, 2025 2024 (Unaudited) (In thousands, except share and per share data)Revenue$172,347 $152,191 Cost of revenue 89,797 73,070 Gross profit 82,550 79,121 Operating expenses: Sales and marketing 16,343 14,173 Research and development 27,503 23,918 General and administrative 12,927 15,798 Total operating expenses 56,773 53,889 Income from operations 25,777 25,232 Interest income 3,339 1,774 Interest expense (1,558) (783)Realized gain from sale of short-term investments - 273 Unrealized loss on short-term investments (1,082) (2,595)Other (expense) income, net (262) 3,080 Income (loss) from equity method investments 952 (520)Income before income taxes 27,166 26,461 Income tax expense (2,153) (4,369)Net income 25,013 22,092 Less: Net income attributable to non-controlling interests 4,633 4,659 Net income attributable to ACM Research, Inc.$20,380 $17,433 Comprehensive income (loss): Net income 25,013 22,092 Foreign currency translation adjustment, net of tax of nil 1,750 (6,829)Comprehensive Income 26,763 15,263 Less: Comprehensive income attributable to non-controlling interests 4,957 3,406 Comprehensive income attributable to ACM Research, Inc.$21,806 $11,857 Net income attributable to ACM Research, Inc. per common share: Basic$0.32 $0.28 Diluted$0.30 $0.26 Weighted average common shares outstanding used in computing per share amounts: Basic 63,267,834 61,367,184 Diluted 66,952,774 66,242,321 ACM RESEARCH, INC.Total Revenue by Product Category and by Region Three Months Ended March 31, 20252024 (Unaudited) ($ in thousands)Single wafer cleaning, Tahoe and semi-critical cleaning equipment$129,569$109,470ECP (front-end and packaging), furnace and other technologies 27,630 25,800Advanced packaging (excluding ECP), services & spares 15,148 16,921Total Revenue by Product Category$172,347$152,191 Three Months Ended March 31, 2025 2024Mainland China$169,053$152,135Other Regions 3,294 56Total Revenue by Region$172,347$152,191 ACM RESEARCH, INC.Reconciliation of GAAP to Non-GAAP Financial Measures As described under “Use of Non-GAAP Financial Measures” above, ACM presents non-GAAP gross margin, operating expenses, operating income, net income attributable to ACM Research, Inc., and basic and diluted earnings per share as supplemental measures to GAAP financial measures, each of which excludes stock-based compensation (“SBC”) from the equivalent GAAP financial line items. In addition, non-GAAP net income attributable to ACM Research, Inc., and basic and diluted earnings per share exclude unrealized gain (loss) on short-term investments. The following tables reconcile gross margin, operating expenses, operating income, net income attributable to ACM Research, Inc., and basic and diluted earnings per share to the related non-GAAP financial measures: Three Months Ended March 31, 20252024 ActualSBCOther non-operating adjustmentsAdjustedActualSBCOther non-operating adjustmentsAdjusted(GAAP)(Non-GAAP)(GAAP)(Non-GAAP) (In thousands) Revenue$172,347 $- $- $172,347 $152,191 $- $- $152,191 Cost of revenue (89,797) (529) - (89,268) (73,070) (781) - (72,289)Gross profit 82,550 (529) - 83,079 79,121 (781) - 79,902 Gross margin 47.9% 0.3% - 48.2% 52.0% 0.5% - 52.5% Operating expenses: Sales and marketing (16,343) (2,157) - (14,186) (14,173) (3,027) - (11,146)Research and development (27,503) (2,775) - (24,728) (23,918) (4,503) - (19,415)General and administrative (12,927) (4,356) - (8,571) (15,798) (6,258) - (9,540)Total operating expenses (56,773) (9,288) - (47,485) (53,889) (13,788) - (40,101)Income (loss) from operations$25,777 $(9,817)$- $35,594 $25,232 $(14,569)$- $39,801 Unrealized loss on short-term investments (1,082) - (1,082) - (2,595) - (2,595) - Net income (loss) attributable to ACM Research, Inc.$20,380 $(9,817)$(1,082)$31,279 $17,433 $(14,569)$(2,595)$34,597 Basic EPS$0.32 $0.49 $0.28 $0.56 Diluted EPS$0.30 $0.46 $0.26 $0.52
Baystreet.ca - Stocks Flat to Start Thursday
Canada's main stock index opened higher on Thursday, tracking a global market rally, on news that the United States was on the verge of signing a trade agreement with Britain. The TSX Composite Index acquired 33.03 points to begin Wednesday at 25,194.21. ...
Baystreet.ca - Futures Travel Higher Ahead of Trade Deal
Futures tied to Canada's main stock index rose on Thursday, tracking a global market rally, spurred by U.S. President Donald Trump's promise of the first trade deal in his global tariff war. The TSX Composite Index climbed 186.46 points to close ...
Baystreet.ca - Indexes Rise on U.S.-Britain Trade Deal
Canada's main stock index opened higher on Thursday, tracking a global market rally, on news that the United States was on the verge of signing a trade agreement with Britain. The TSX Composite Index acquired 33.03 points to begin Wednesday at 25,194.21. ...
Trump Sparks Risk-On Sentiment Amid US-China Trade Talks Hints - Action Forex
US President Trump reignited risk-on sentiment across global markets on 8 May, coinciding with the announcement of a US–UK trade deal framework. During a White House press Q&A, he hinted at the possibility of lowering China tariffs if upcoming trade talks in Switzerland go well. He added, “You better go out and buy stock now,” echoing a similar statement from 9 April: “This is a great time to buy.”